Teriparatide (Forteo, PTH 1-34)

1. Overview

Teriparatide is the recombinant form of the N-terminal 34-amino acid fragment of human parathyroid hormone (PTH(1-34)), representing the biologically active portion of the full 84-amino acid PTH molecule [16][17]. Its amino acid sequence is: Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe. The molecular formula is C181H291N55O51S2 with a molecular weight of 4117.8 Da. The peptide adopts an N-terminal alpha-helix (residues 3-13) and a longer C-terminal helix (residues 17-34) connected by a flexible hinge region stabilized by hydrophobic interactions [16].

Teriparatide was the first anabolic agent approved for osteoporosis treatment. It received FDA approval on November 26, 2002, under the brand name Forteo (Eli Lilly and Company) for the treatment of osteoporosis in postmenopausal women and men at high risk of fracture [9][16]. In 2009, the indication was expanded to include glucocorticoid-induced osteoporosis (GIO) in men and women [5]. Outside the United States, the drug is marketed as Forsteo in Europe and other regions.

The drug is administered as a once-daily 20 mcg subcutaneous injection to the thigh or abdominal wall using a multidose prefilled pen device. Following subcutaneous injection, teriparatide is rapidly absorbed, reaching peak serum concentrations (Cmax) within approximately 30 minutes, with a bioavailability of approximately 95% [16]. The elimination half-life is approximately 1 hour, and the peptide is cleared through hepatic and extrahepatic mechanisms with a systemic clearance rate of approximately 62 L/h. This rapid pharmacokinetic profile -- transient peak followed by quick elimination -- is fundamental to the drug's anabolic mechanism.

Molecular Weight

4117.8 Da

Molecular Formula

C181H291N55O51S2

Sequence

34 amino acids (N-terminal fragment of 84-aa PTH)

Half-life

~1 hour (subcutaneous)

Bioavailability

~95% (subcutaneous)

Routes

Subcutaneous injection (approved)

FDA Status

Approved (Forteo, November 2002; black box removed November 2020)

Approved Indications

Postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis (high fracture risk)

2. Mechanism of Action

Teriparatide exerts its effects through activation of the parathyroid hormone type 1 receptor (PTH1R), a class B G protein-coupled receptor (GPCR) expressed on osteoblasts, osteocytes, and renal tubular cells [16][17]. The distinction between its anabolic and catabolic potential lies entirely in the pattern of receptor exposure: intermittent (pulsatile) PTH1R activation stimulates net bone formation, while continuous PTH1R activation -- as occurs in primary hyperparathyroidism -- promotes net bone resorption.

Intermittent versus continuous exposure. When administered as a once-daily injection, teriparatide produces a brief pulse of PTH1R activation lasting approximately 2-4 hours [17][22]. This intermittent exposure preferentially activates the cAMP/protein kinase A (PKA) signaling pathway via Gs-alpha coupling, which drives osteoblast differentiation, proliferation, and survival. By contrast, continuous PTH exposure (as demonstrated in rodent infusion studies) predominantly activates RANKL expression in osteoblasts and osteocytes, promoting osteoclastogenesis and resorption [17]. In classic experiments, rats administered teriparatide once daily showed enhanced osteoblastic activity, while those receiving continuous infusion showed enhanced osteoclast activity.

The anabolic window. Following initiation of teriparatide therapy, bone formation markers (particularly P1NP, procollagen type I N-terminal propeptide) rise rapidly, peaking between 1 and 6 months of treatment [16][20]. Bone resorption markers (CTX, C-terminal telopeptide of type I collagen) also increase, but with a temporal delay and to a lesser magnitude, creating a net positive balance termed the "anabolic window" [22]. This window of predominantly formative activity is most pronounced during the first 6-12 months of therapy and gradually narrows as resorption catches up with formation. The anabolic window concept explains why early treatment effects on BMD are steepest and why sequential therapy with an antiresorptive agent is critical after teriparatide discontinuation.

Wnt/beta-catenin signaling and sclerostin suppression. Intermittent PTH powerfully modulates the canonical Wnt signaling pathway, a master regulator of osteoblast differentiation and bone formation [18][19]. PTH1R activation directly suppresses osteocyte expression of sclerostin (encoded by the SOST gene), a secreted glycoprotein that normally inhibits Wnt signaling by binding to the LRP5/6 co-receptor on osteoblast precursors [18][19]. Bellido et al. (2005) demonstrated that PTH reduces sclerostin expression in osteocytes, thereby releasing the brake on Wnt/beta-catenin signaling and allowing osteoblast precursor proliferation and differentiation to proceed [19]. Additionally, PTH suppresses expression of Dickkopf-1 (DKK1), another Wnt antagonist, further amplifying the pro-osteoblastic signal.

Osteoblast activation and survival. Beyond Wnt pathway modulation, teriparatide stimulates osteoblast activity through multiple complementary mechanisms [17][20]: (1) upregulation of insulin-like growth factor 1 (IGF-1) and fibroblast growth factor 2 (FGF-2), which act as local osteoblastogenic growth factors; (2) increased expression and activity of Runx2/Cbfa1, a transcription factor essential for osteoblast differentiation; (3) inhibition of osteoblast apoptosis via activation of pro-survival signaling; and (4) recruitment of mesenchymal stem cells to bone surfaces and conversion of quiescent bone-lining cells to active osteoblasts [20]. Lindsay et al. (2007) demonstrated that even a single month of PTH(1-34) treatment stimulated bone formation on cancellous, endocortical, and periosteal surfaces of human iliac bone [20].

Regulatory T cell expansion. An additional mechanism identified in both preclinical and clinical studies involves the expansion of regulatory T cells (Tregs). Li et al. (2017) showed that intermittent PTH induces a 2-3 fold increase in CD4+CD25+FoxP3+ Tregs, and that blockade of this expansion abrogated the bone anabolic effect of intermittent PTH in mice. These Tregs stimulate Wnt10b production by CD8+ T cells, further activating Wnt-dependent osteoblastogenesis.

Bone turnover marker dynamics. In clinical use, P1NP (the preferred formation marker) peaks at 1-3 months then declines toward baseline by 12-24 months while remaining above pretreatment levels [16]. Osteocalcin follows a similar trajectory. CTX rises more gradually, typically peaking at 6-12 months. Serum P1NP response at 3 months has been proposed as an early indicator of treatment response, with increases exceeding 10 mcg/L correlating with meaningful BMD gains at 18-24 months.

3. Researched Applications

Postmenopausal Osteoporosis at High Fracture Risk (Strong Evidence -- FDA Approved)

The Neer 2001 Fracture Prevention Trial (FPT) was the landmark study establishing teriparatide's clinical efficacy [1]. This Phase 3, randomized, double-blind, placebo-controlled trial enrolled 1,637 postmenopausal women with at least one prior vertebral fracture. Participants were randomized to teriparatide 20 mcg/day, teriparatide 40 mcg/day, or placebo by subcutaneous injection. Over a median treatment duration of 21 months (the trial was terminated early due to the rodent osteosarcoma finding), teriparatide 20 mcg reduced new vertebral fractures by 65% (relative risk 0.35; 95% CI 0.22-0.55; p<0.001) and nonvertebral fragility fractures by 53% (RR 0.47; 95% CI 0.25-0.88; p=0.02) [1]. Lumbar spine BMD increased by 9.7% and femoral neck BMD by 2.8% in the 20 mcg group. The 40 mcg dose produced numerically greater BMD gains (13.7% at spine) but with more adverse events and without additional fracture benefit, establishing 20 mcg as the therapeutic dose.

Severe Osteoporosis -- Head-to-Head vs Antiresorptive (Strong Evidence)

The VERO trial was the first randomized, double-blind, double-dummy, active-controlled trial to compare teriparatide directly against an antiresorptive agent with fracture endpoints [2][10][25]. A total of 1,360 postmenopausal women with at least two moderate or one severe vertebral fracture and BMD T-score of -1.5 or lower were randomized to teriparatide 20 mcg SC daily or risedronate 35 mg oral weekly for 24 months. Teriparatide significantly reduced new vertebral fractures compared to risedronate (5.4% vs 12.0%; RR 0.44; 95% CI 0.29-0.68; p<0.0001) [2]. Clinical fractures were also significantly reduced (4.8% vs 9.8%; HR 0.48; 95% CI 0.32-0.74; p=0.0009). FRAX-defined major osteoporotic fracture risk was reduced by 60% with teriparatide versus risedronate [25]. VERO provided the strongest evidence that anabolic therapy should be first-line for patients with severe osteoporosis and high imminent fracture risk.

Glucocorticoid-Induced Osteoporosis (Strong Evidence -- FDA Approved)

The GIO trial randomized 428 men and women (ages 22-89) receiving chronic glucocorticoids (at least 5 mg/day prednisone equivalent for 3 or more months) to teriparatide 20 mcg daily or alendronate 10 mg daily for 18 months (subsequently extended to 36 months) [5]. At 18 months, teriparatide produced significantly greater lumbar spine BMD increases (7.2% vs 3.4%; p<0.001). Critically, fewer patients in the teriparatide group sustained new vertebral fractures (0.6% vs 6.1%; p=0.004) [5]. At 36 months, the differences widened further. This led to FDA approval of teriparatide for GIO in 2009.

Combination Therapy with Denosumab (Moderate-Strong Evidence)

The DATA study program (Denosumab and Teriparatide Administration) systematically evaluated monotherapy and combination approaches [3][4][11]. In the initial DATA trial, 94 postmenopausal women were randomized to teriparatide alone, denosumab alone, or both agents combined for 24 months [3]. At 12 months, lumbar spine BMD increased by 9.1% in the combination group versus 6.2% with teriparatide alone and 5.5% with denosumab alone [3]. At 24 months, combination therapy produced greater BMD increases than either monotherapy at all measured skeletal sites, including the spine (12.9%), total hip (6.3%), and femoral neck (6.8%) [11].

The DATA-HD extension demonstrated that combining denosumab with high-dose teriparatide (40 mcg) produced even greater spine BMD gains than the standard-dose combination, representing the largest reported BMD increases with any osteoporosis treatment regimen [4].

Male Osteoporosis (Strong Evidence -- FDA Approved)

Orwoll et al. (2003) conducted a randomized, double-blind trial in 437 men with osteoporosis (BMD T-score <-2.0), demonstrating that teriparatide 20 mcg daily for a median of 11 months significantly increased lumbar spine BMD by 5.9% and femoral neck BMD by 1.5% versus placebo [12]. These results supported FDA approval for male osteoporosis as part of the initial 2002 label.

Real-World Evidence (Strong Evidence)

The European Forsteo Observational Study (EFOS) prospectively followed 1,648 postmenopausal women treated with teriparatide in routine clinical practice across eight European countries for 18 months [6]. A 47% reduction in the odds of fracture was observed between the first and last 6-month treatment periods. Back pain VAS scores decreased by 25.8 mm, and quality of life improved significantly. The Extended Forsteo Observational Study (ExFOS) confirmed sustained benefits at 24 months in a real-world population.

4. Pharmacokinetics

Teriparatide has a distinctive pharmacokinetic profile characterized by rapid absorption, high bioavailability, brief systemic exposure, and fast clearance -- properties that are not merely incidental but are fundamental to its anabolic mechanism of action [16][17][22].

Absorption. Following subcutaneous injection of 20 mcg into the thigh or abdominal wall, teriparatide is rapidly absorbed with an absolute bioavailability of approximately 95%, one of the highest among peptide therapeutics [16]. Peak serum concentrations (Cmax) of approximately 35-40 pg/mL (above baseline endogenous PTH) are reached within approximately 30 minutes (Tmax), closely approximating the kinetics of a physiological PTH secretory burst. The high bioavailability reflects the small molecular weight (4,118 Da) and favorable physicochemical properties of the peptide for subcutaneous absorption.

Distribution. The volume of distribution at steady state is approximately 0.12 L/kg, consistent with distribution primarily within the extracellular fluid. Teriparatide binds to PTH1R on osteoblasts, osteocytes, and renal tubular cells, with receptor engagement initiating the intracellular signaling cascades that drive the anabolic response [16][17]. The brief duration of receptor occupancy (approximately 2-4 hours of supraphysiological PTH1R activation after each injection) is the key determinant of the anabolic versus catabolic outcome.

Metabolism and elimination. Teriparatide is rapidly cleared through both hepatic and extrahepatic mechanisms, with a systemic clearance of approximately 62 L/h -- far exceeding hepatic plasma flow, indicating substantial peripheral (likely renal and skeletal) proteolytic degradation [16]. The elimination half-life is approximately 1 hour following subcutaneous administration, and serum concentrations return to baseline within 3-4 hours post-injection. This rapid clearance is not a limitation but a pharmacokinetic asset: the brief, pulsatile exposure pattern distinguishes the anabolic effect of once-daily teriparatide from the catabolic effects of continuous PTH elevation seen in hyperparathyroidism [17][22].

Dose proportionality. In the Neer FPT, both 20 mcg and 40 mcg doses were studied, demonstrating dose-proportional increases in Cmax and AUC [1]. The 40 mcg dose produced approximately double the systemic exposure and greater BMD gains at the spine (13.7% vs 9.7%) but without additional fracture reduction benefit, while producing more adverse events (hypercalcemia, nausea), establishing 20 mcg as the optimal therapeutic dose [1][16].

Renal impairment. No dose adjustment is required for mild-to-moderate renal impairment. In severe renal insufficiency (CrCl less than 30 mL/min), teriparatide clearance is reduced by approximately 28%, resulting in modestly increased exposure, but clinical data in this population are limited [16].

The "pulsatile exposure" paradigm. The pharmacokinetic profile of teriparatide -- rapid absorption (Tmax 30 minutes), high peak (Cmax approximately 35-40 pg/mL above baseline), and fast elimination (t1/2 approximately 1 hour) -- creates a sharp, transient pulse of PTH1R activation lasting approximately 2-4 hours [17][22]. This pulsatile pattern preferentially activates the cAMP/PKA/CREB signaling cascade that drives osteoblast differentiation and survival, while the rapid return to baseline prevents sustained RANKL upregulation that would promote osteoclastogenesis. The pharmacokinetic profile is thus inextricably linked to the pharmacodynamic mechanism: continuous-infusion PTH (mimicking hyperparathyroidism) produces net bone loss, while once-daily injection (mimicking teriparatide) produces net bone gain. This principle has been confirmed in both preclinical infusion studies and in the clinical observation that patients with primary hyperparathyroidism (continuous PTH elevation) lose cortical bone despite trabecular preservation.

5. Dose-Response Relationships

BMD dose-response. The Neer FPT evaluated two dose levels (20 mcg and 40 mcg daily) against placebo in 1,637 postmenopausal women [1]:

| Endpoint | Placebo | 20 mcg | 40 mcg | |---|---|---|---| | Lumbar spine BMD change | +1.1% | +9.7% | +13.7% | | Femoral neck BMD change | -0.7% | +2.8% | +5.1% | | Total hip BMD change | -1.0% | +2.6% | +3.6% | | New vertebral fracture | 14.3% | 5.0% (RR 0.35) | 4.4% (RR 0.31) | | Nonvertebral fracture | 6.9% | 3.3% (RR 0.47) | 5.5% (RR 0.80) |

The BMD dose-response is clearly dose-dependent at all skeletal sites, with the 40 mcg dose producing approximately 40% greater BMD gains than 20 mcg at the spine [1]. However, the fracture dose-response is not linear: the 40 mcg dose did not produce additional vertebral fracture reduction beyond 20 mcg and showed a numerically higher nonvertebral fracture rate than 20 mcg. This disconnect between BMD and fracture dose-response led to the selection of 20 mcg as the approved dose [1][16].

Bone marker dose-response. P1NP (procollagen type I N-terminal propeptide), the preferred bone formation marker, shows a dose-dependent rise that peaks between 1 and 6 months of therapy [16][22]. At 20 mcg, P1NP typically increases 100-200% above baseline within the first 3 months; at 40 mcg, the increase is approximately 200-400%. CTX (C-terminal telopeptide, a resorption marker) also rises dose-dependently but with a temporal delay, creating the "anabolic window" during which formation exceeds resorption.

Hypercalcemia dose-response. The incidence of transient hypercalcemia (serum calcium above 10.6 mg/dL at 4-6 hours post-dose) was clearly dose-dependent: 2% (placebo), 11% (20 mcg), and 28% (40 mcg) in the Neer FPT [1]. This approximately 2.5-fold increase in hypercalcemia risk with dose doubling was a significant factor favoring the 20 mcg dose.

Duration-response. BMD gains with teriparatide are steepest during the first 12 months of therapy, reflecting the initial anabolic window when formation markers substantially exceed resorption markers [16][22]. Between 12 and 24 months, BMD continues to increase but at a diminishing rate as the resorption-formation coupling narrows the anabolic window. The DATA-HD study demonstrated that 40 mcg combined with denosumab produced the largest BMD increases ever reported with any osteoporosis regimen, suggesting that higher doses may be more beneficial when coupled with concurrent antiresorptive therapy that prevents the resorptive component from narrowing the anabolic window [4].

Weekly dosing. In Japan, a 56.5 mcg once-weekly regimen is approved based on the TOWER trial, which demonstrated vertebral fracture reduction. The weekly regimen produces a larger but less frequent PTH pulse. Comparative data suggest that daily dosing may produce greater cortical bone gains, while weekly dosing may be more convenient with comparable vertebral fracture efficacy.

6. Comparative Effectiveness

Teriparatide vs Abaloparatide

Abaloparatide (Tymlos) is the most directly comparable agent -- both are 34-amino acid PTH1R agonists administered as once-daily subcutaneous injections [13][22]:

| Parameter | Teriparatide (20 mcg) | Abaloparatide (80 mcg) | |---|---|---| | Molecular origin | PTH(1-34) fragment | PTHrP(1-34) analog | | Receptor conformation | Binds RG and R0 states of PTH1R | Preferentially binds RG (transient) state | | Lumbar spine BMD at 18 months | +9.2% (FPT) | +11.2% (ACTIVE) | | Total hip BMD at 18 months | +2.6% (FPT) | +4.2% (ACTIVE) | | Vertebral fracture reduction vs placebo | 65% (RR 0.35) | 86% (RR 0.14) | | Nonvertebral fracture reduction | 53% (RR 0.47) | 43% (RR 0.57) | | Hypercalcemia incidence | 6.4% (ACTIVE open-label arm) | 3.4% (ACTIVE) | | Treatment duration limit | None (removed 2020) | 2 years |

Important caveats: the ACTIVE trial included an open-label teriparatide arm, preventing direct blinded comparison of fracture endpoints between the two agents. No head-to-head double-blind trial exists. The lower hypercalcemia rate with abaloparatide is attributed to its preferential binding to the RG (transient signaling) conformation of PTH1R, producing shorter-duration receptor activation [13][22].

Teriparatide vs Romosozumab

Romosozumab (Evenity) represents a fundamentally different anabolic approach -- anti-sclerostin monoclonal antibody therapy [7][14][15][22]:

| Parameter | Teriparatide | Romosozumab (210 mg monthly) | |---|---|---| | Mechanism | PTH1R agonist (remodeling-based formation) | Anti-sclerostin antibody (modeling-based formation) | | Duration of anabolic effect | Up to 24 months | 12 months (then transition to antiresorptive) | | Spine BMD at 12 months | +9.5% (VERO) | +13.3% (FRAME) | | Total hip BMD at 12 months | +2.0% (estimated) | +6.9% (FRAME) | | STRUCTURE trial (post-bisphosphonate) | Spine +5.4%, hip -0.6% | Spine +9.8%, hip +2.6% | | Cardiovascular signal | None | MACE signal in ARCH (HR 1.87 vs alendronate) | | Treatment course | 24 months | 12 months | | Route | SC daily | SC monthly |

Key differentiators: Romosozumab produces faster and greater BMD gains, particularly at the hip, and is superior to teriparatide specifically in bisphosphonate-pretreated patients (STRUCTURE trial) [7]. However, romosozumab carries a cardiovascular safety signal (increased MACE observed in the ARCH trial compared to alendronate) that led to a boxed warning and contraindication in patients with recent MI or stroke [15]. Teriparatide has no cardiovascular safety signal and has a longer treatment course (24 months vs 12 months). The choice between agents depends on treatment history (romosozumab preferred post-bisphosphonate), cardiovascular risk profile, and the relative urgency of BMD improvement.

Sequential Therapy Considerations

The DATA-Switch study established that the optimal sequence is anabolic-first followed by antiresorptive consolidation [11][21][22]:

• Teriparatide then denosumab: BMD gains from teriparatide are maintained and extended
• Denosumab then teriparatide: Transient spine and hip BMD loss during the first 12 months of teriparatide, partially recovering by 24 months
• Teriparatide then bisphosphonate: BMD generally maintained but may plateau
• No follow-on therapy after teriparatide: Rapid BMD loss, approaching pre-treatment levels within 12-24 months

These sequencing data have fundamentally shaped the "anabolic-first" paradigm in modern osteoporosis management [8][11][21].

7. Enhanced Safety Profile

The safety database for teriparatide encompasses over 4,000 patients in randomized clinical trials and approximately 2.47 million treated patients in post-marketing surveillance, providing one of the most robust safety profiles among osteoporosis therapies [1][9][16][23].

Resolution of the osteosarcoma concern. The rodent osteosarcoma finding that shaped teriparatide's regulatory history for nearly two decades has been definitively resolved [9][23]. Fischer 344 rats exposed to teriparatide at 3-58 times the human dose for near-lifetime durations (up to 2 years, representing approximately 80% of the rat lifespan) developed osteosarcoma in up to 45% of animals. However, multiple lines of evidence established that this finding is not relevant to human therapeutic use: (1) rats have open growth plates and fundamentally different skeletal biology than adult humans; (2) the doses used in rats were far above the human therapeutic range; (3) rat exposure durations (near-lifetime) far exceed human treatment courses; and (4) the completed 15-year FDA-mandated post-marketing surveillance study (2003-2019), encompassing approximately 2.47 million teriparatide-treated patients, found that the incidence of osteosarcoma did not exceed the background population rate (approximately 3.4 per million per year) [9][23]. On November 16, 2020, the FDA removed the osteosarcoma boxed warning and the 2-year cumulative lifetime use limitation.

Hypercalcemia management. Transient hypercalcemia occurs in approximately 11% of patients at the 20 mcg dose, typically peaking at 4-6 hours post-injection and resolving by 16-24 hours [1][16]. The hypercalcemia is a direct pharmacological effect of PTH1R-mediated stimulation of renal calcium reabsorption and intestinal calcium absorption. Clinical significance is generally low: levels rarely exceed 11.5 mg/dL, and symptomatic hypercalcemia is uncommon. Serum calcium should be measured before treatment and monitored periodically. Patients should maintain adequate hydration and avoid excessive calcium supplementation (more than 1,000 mg/day total from diet and supplements).

Orthostatic hypotension. Transient decreases in blood pressure following injection are attributable to PTH1R-mediated vasodilation and have been reported in approximately 5% of patients [1][16]. The effect is most pronounced during the first several doses and diminishes with continued use. Patients should be counseled to sit or lie down for injection and remain seated for several minutes afterward.

Musculoskeletal effects. Leg cramps (2.6%), arthralgia, and pain in extremity are reported at modestly higher rates than placebo and may reflect the skeletal remodeling stimulated by teriparatide [1][16]. These effects are generally mild and do not require treatment discontinuation.

No cardiovascular safety signal. Unlike romosozumab, which carries a boxed warning for cardiovascular risk based on the ARCH trial MACE signal, teriparatide has shown no increased cardiovascular risk across clinical trials or post-marketing surveillance [1][9][15]. This clean cardiovascular profile makes teriparatide the preferred anabolic agent for patients with recent cardiovascular events or high cardiovascular risk.

Urolithiasis. An increase in urinary calcium excretion (hypercalciuria) occurs with teriparatide therapy, potentially increasing the risk of calcium nephrolithiasis. Teriparatide should be used cautiously in patients with active or recent urolithiasis, pre-existing hypercalciuria, or predisposition to stone formation [16].

Long-term safety beyond 2 years. With the removal of the 2-year treatment limit in 2020, long-term safety data are accumulating for extended courses [9]. Available evidence from extended clinical trials (DATA 24-month, GIO 36-month) and post-marketing experience does not suggest increased risk with treatment beyond 2 years, though dedicated long-term safety studies of extended courses are limited.

8. Clinical Evidence Summary

9. Sequential and Combination Therapy

The concept of sequential therapy is critically important with teriparatide. BMD gains achieved during teriparatide treatment are rapidly lost if no antiresorptive agent is initiated upon discontinuation [8][21][22].

Post-teriparatide antiresorptive consolidation. The DATA-Follow-up study demonstrated that BMD gains were maintained and even extended when patients transitioned from teriparatide to denosumab, but were partially lost when teriparatide was simply stopped without follow-on therapy [8]. Current clinical guidelines uniformly recommend transitioning to a bisphosphonate (alendronate, zoledronic acid) or denosumab immediately after completing teriparatide therapy.

Prior bisphosphonate use blunts response. Patients transitioning from bisphosphonates to teriparatide experience a blunted BMD response, particularly at the hip, where transient BMD loss during the first 6-12 months of teriparatide has been documented [7][24]. This bisphosphonate-to-anabolic transition effect is attributed to the residual antiresorptive effect of bisphosphonates suppressing the coupled bone remodeling required for teriparatide's anabolic action.

Sequencing principles established by DATA-Switch. The DATA-Switch study established the principle that teriparatide followed by denosumab produces the most favorable BMD trajectory, while switching from denosumab to teriparatide causes transient bone loss [11]. This has fundamentally shaped the current consensus that anabolic therapy should be used first ("anabolic-first" paradigm), followed by antiresorptive consolidation.

Comparison with romosozumab (STRUCTURE trial). In the STRUCTURE trial, 436 bisphosphonate-pretreated postmenopausal women were randomized to romosozumab 210 mg SC monthly or teriparatide 20 mcg SC daily for 12 months [7]. Romosozumab produced significantly greater BMD gains at both the total hip (2.6% vs -0.6%) and lumbar spine (9.8% vs 5.4%), demonstrating that romosozumab is superior to teriparatide specifically in the bisphosphonate-pretreated population. This further supports the concept that the choice of anabolic agent may depend on the patient's treatment history.

10. Comparison with Other Anabolic Agents

Teriparatide vs Abaloparatide (Tymlos)

Abaloparatide is a synthetic 34-amino acid analog of PTH-related protein (PTHrP(1-34)), not a biosimilar of teriparatide [13]. Despite a common misconception (sometimes termed "Tymlos confusion"), abaloparatide is a molecularly distinct compound with a different amino acid sequence derived from PTHrP rather than PTH. Both agents activate PTH1R, but abaloparatide preferentially binds the RG (transient signaling) conformation of the receptor, while teriparatide also engages the R0 (sustained signaling) conformation [13]. This results in abaloparatide producing more transient cAMP signaling, clinically translating to lower incidence of hypercalcemia (3.4% vs 6.4% in ACTIVE) and potentially a wider anabolic window. In the ACTIVE trial, abaloparatide produced numerically greater hip BMD gains and lower rates of hypercalcemia compared to open-label teriparatide, although direct fracture endpoint comparisons were limited by the open-label teriparatide arm design [13].

Teriparatide vs Romosozumab (Evenity)

Romosozumab is a monoclonal antibody against sclerostin, acting through a fundamentally different mechanism -- it inhibits the same molecule (sclerostin) that teriparatide downregulates via PTH1R signaling [14][15]. Romosozumab primarily stimulates modeling-based bone formation (formation without prior resorption), while teriparatide predominantly activates remodeling-based formation (formation coupled to resorption) [22]. In the FRAME trial, romosozumab 210 mg monthly for 12 months reduced vertebral fractures by 73% versus placebo [14]. In the ARCH trial, romosozumab followed by alendronate was superior to alendronate alone in preventing both vertebral (6.2% vs 11.9%) and nonvertebral fractures, though a cardiovascular safety signal (increased MACE risk, RR 1.87) was observed [15]. The STRUCTURE trial showed romosozumab's superiority over teriparatide in bisphosphonate-pretreated patients at the hip [7]. Romosozumab has a 12-month treatment course versus teriparatide's 24-month course.

11. Dosing in Research

The FDA-approved dose is 20 mcg administered once daily by subcutaneous injection into the thigh or abdominal wall [1][16]. Treatment was originally limited to a cumulative 2-year lifetime exposure, but this restriction was removed in the November 2020 label update based on the absence of osteosarcoma signal in human post-marketing data [9].

In the Neer FPT, both 20 mcg and 40 mcg doses were studied; the 20 mcg dose was selected for clinical use based on the superior risk-benefit profile [1]. In Japan, an alternative once-weekly 56.5 mcg regimen is approved and has demonstrated efficacy in the TOWER trial.

The DATA-HD study explored 40 mcg teriparatide in combination with denosumab, demonstrating greater BMD gains than the standard 20 mcg combination, suggesting potential for high-dose use in investigational settings [4].

Teriparatide should be injected into a site with adequate subcutaneous tissue. Patients are advised to administer the injection while sitting or lying down and should remain in that position for several minutes after injection to mitigate orthostatic effects. The multidose pen delivers 20 mcg per injection and provides a 28-day supply when stored refrigerated at 2-8 degrees Celsius.

12. Safety and Side Effects

The safety profile of teriparatide has been extensively characterized through clinical trials involving more than 4,000 patients and post-marketing surveillance encompassing approximately 2.47 million treated patients worldwide [1][9][23].

Common adverse reactions. The most frequently reported adverse events include nausea (8.5%), headache (7.5%), dizziness (8.0%), leg cramps (2.6%), arthralgia, and pain in extremity [1][16]. Injection site reactions are generally mild and infrequent.

Hypercalcemia. Transient hypercalcemia is a known pharmacological effect of PTH1R activation. In the Neer FPT, at least one episode of serum calcium above the upper limit of normal (measured 4-6 hours post-dose) occurred in 11% of women treated with teriparatide 20 mcg versus 2% in the placebo group [1]. Hypercalcemia was generally mild and transient, resolving without dose modification. Severe hypercalcemia (above 13 mg/dL) is rare. Serum calcium should be measured before treatment initiation and monitored periodically.

Orthostatic hypotension. Teriparatide can cause transient decreases in blood pressure after injection. Patients should be counseled to sit or lie down if lightheadedness or palpitations occur.

Urolithiasis. An increase in urinary calcium excretion has been reported. Teriparatide should be used with caution in patients with active or recent urolithiasis.

Osteosarcoma -- historical context and resolution. The original Forteo approval in 2002 carried a black box warning for potential osteosarcoma risk based on preclinical findings in Fischer 344 rats, where near-lifetime exposure to high-dose teriparatide (3-58 times the human dose based on surface area) produced osteosarcoma in up to 45% of animals [9][23]. This led to the 2-year treatment limit and a mandatory 15-year post-marketing osteosarcoma surveillance study. The completed surveillance (2003-2019), covering approximately 2.47 million teriparatide-treated patients, found that the incidence rate of osteosarcoma in teriparatide-treated patients did not exceed the background population rate [23]. Based on the totality of evidence -- the biological differences between rodent and human skeletal physiology (rats have open growth plates and much higher baseline bone turnover), the extreme doses used in rat studies, and 15+ years of negative human surveillance data -- the FDA approved removal of the osteosarcoma boxed warning and the 2-year treatment limitation on November 16, 2020 [9].

Contraindications. Teriparatide remains contraindicated in patients with hypersensitivity to teriparatide, Paget's disease of bone, unexplained elevations of alkaline phosphatase, open epiphyses (children and young adults), prior external beam or implant radiation therapy involving the skeleton, pre-existing hypercalcemia, and bone metastases or pre-existing skeletal malignancies.

13. Biosimilars and Follow-On Products

Several teriparatide biosimilars and follow-on products have been approved globally:

European Union. The EMA approved the first teriparatide biosimilars in January 2017: Terrosa (Gedeon Richter) and Movymia (Stada Arzneimittel), both launched in 2019. Subsequent approvals included Livogiva (Theramex, 2020), Sondelbay (Accord Healthcare, 2022), and Kauliv (Strides Pharma, 2023). These biosimilars have demonstrated analytical, pharmacokinetic, and clinical similarity to the reference product Forsteo.

United States. In October 2019, the FDA approved a follow-on teriparatide product (PF708, originally developed by Pfenex/Alvogen), though this was approved through the 505(b)(2) regulatory pathway rather than the biosimilar pathway under the Biologics Price Competition and Innovation Act (BPCIA). The Forteo patent expired in the US in 2019.

Important clarification. Abaloparatide (Tymlos) is sometimes confused with teriparatide biosimilars, but it is a distinct molecule -- a PTHrP(1-34) analog with a different amino acid sequence, different receptor binding profile, and its own independent clinical development program [13].

Biosimilar clinical equivalence (2025 data). A study published in Osteoporosis International confirmed that the teriparatide biosimilar RGB-10 (Terrosa) and reference teriparatide showed consistent therapeutic effects in postmenopausal women with osteoporosis at very high fracture risk, with no significant differences observed between the two treatments across bone health measures at 12 and 24 months. A separate retrospective cohort study using Japanese data further confirmed comparable safety profiles with no significant differences in fracture risk or osteosarcoma incidence between biosimilar and originator teriparatide.

14. Regulatory Status

United States (FDA). Teriparatide (Forteo) was approved on November 26, 2002, for postmenopausal women with osteoporosis at high risk of fracture and for men with primary or hypogonadal osteoporosis at high risk of fracture [9][16]. The glucocorticoid-induced osteoporosis indication was added in 2009 [5]. On November 16, 2020, the FDA approved major label updates: removal of the osteosarcoma boxed warning and the 2-year cumulative lifetime use limitation, based on the completed 15-year post-marketing surveillance study [9].

European Union (EMA). Forsteo was approved by the European Commission in June 2003 for treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture, and for glucocorticoid-induced osteoporosis.

Japan. Teriparatide is approved in both a daily 20 mcg formulation and a unique once-weekly 56.5 mcg formulation based on the TOWER trial data.

Global availability. Teriparatide has been approved in more than 90 countries worldwide and is included in all major osteoporosis treatment guidelines (AACE/ACE, Endocrine Society, NOGG, IOF) as a recommended anabolic agent for patients at high or very high fracture risk.

15. Related Peptides

See also: Abaloparatide (Tymlos), Calcitonin

16. References

1. [1] Neer RM, Arnaud CD, Zanchetta JR, et al. (2001). Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis. N Engl J Med. DOI PubMed
2. [2] Kendler DL, Marin F, Zerbini CAF, et al. (2018). Effects of Teriparatide and Risedronate on New Fractures in Post-Menopausal Women with Severe Osteoporosis (VERO). Lancet. DOI PubMed
3. [3] Leder BZ, Tsai JN, Uihlein AV, et al. (2013). Teriparatide and Denosumab, Alone or Combined, in Women with Postmenopausal Osteoporosis (the DATA Study Randomised Trial). Lancet. DOI PubMed
4. [4] Leder BZ, Tsai JN, Uihlein AV, et al. (2019). Combination Denosumab and High Dose Teriparatide for Postmenopausal Osteoporosis (DATA-HD). Lancet Diabetes Endocrinol. DOI PubMed
5. [5] Saag KG, Shane E, Boonen S, et al. (2007). Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis. N Engl J Med. DOI PubMed
6. [6] Langdahl BL, Rajzbaum G, Jakob F, et al. (2009). Reduction in Fracture Rate and Back Pain and Increased Quality of Life in Postmenopausal Women Treated with Teriparatide (18-Month Data from EFOS). Calcif Tissue Int. DOI PubMed
7. [7] Langdahl BL, Libanati C, Zanchetta JR, et al. (2017). Romosozumab (Sclerostin Monoclonal Antibody) versus Teriparatide in Postmenopausal Women with Osteoporosis Transitioning from Oral Bisphosphonate Therapy (STRUCTURE). Lancet. DOI PubMed
8. [8] Leder BZ, Tsai JN, Jiang LA, Lee H. (2017). Importance of Prompt Antiresorptive Therapy in Postmenopausal Women Discontinuing Teriparatide or Denosumab (DATA-Follow-up). J Bone Miner Res. DOI PubMed
9. [9] Krege JH, Gilsenan AW, Goss PE, et al. (2022). Teriparatide and Osteosarcoma Risk -- History, Science, Elimination of Boxed Warning, and Other Label Updates. JBMR Plus. DOI PubMed
10. [10] Geusens P, Marin F, Kendler DL, et al. (2018). Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis (VERO Subgroup Analysis). J Bone Miner Res. DOI PubMed
11. [11] Tsai JN, Uihlein AV, Lee H, et al. (2015). Teriparatide and Denosumab, Alone or Combined, in Women with Postmenopausal Osteoporosis (the DATA Study -- Two-Year Results). J Clin Endocrinol Metab. DOI PubMed
12. [12] Orwoll ES, Scheele WH, Paul S, et al. (2003). The Effect of Teriparatide Therapy on Bone Density in Men with Osteoporosis. J Bone Miner Res. DOI PubMed
13. [13] Miller PD, Hattersley G, Riis BJ, et al. (2016). Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women with Osteoporosis (ACTIVE Trial). JAMA. DOI PubMed
14. [14] Cosman F, Crittenden DB, Adachi JD, et al. (2016). Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. DOI PubMed
15. [15] Saag KG, Petersen J, Brandi ML, et al. (2017). Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis (ARCH Trial). N Engl J Med. DOI PubMed
16. [16] Hodsman AB, Bauer DC, Dempster DW, et al. (2005). Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis -- A Review of the Evidence and Suggested Guidelines. Endocr Rev. DOI PubMed
17. [17] Jilka RL. (2007). Molecular and Cellular Mechanisms of the Anabolic Effect of Intermittent PTH. Bone. DOI PubMed
18. [18] Keller H, Kneissel M. (2005). SOST Is a Target Gene for PTH in Bone. Bone. DOI PubMed
19. [19] Bellido T, Ali AA, Gubrij I, et al. (2005). Chronic Elevation of Parathyroid Hormone in Mice Reduces Expression of Sclerostin by Osteocytes. Proc Natl Acad Sci USA. DOI PubMed
20. [20] Lindsay R, Zhou H, Cosman F, et al. (2007). Effects of a One-Month Treatment with PTH(1-34) on Bone Formation on Cancellous, Endocortical, and Periosteal Surfaces of the Human Ilium. J Bone Miner Res. DOI PubMed
21. [21] Cosman F. (2014). Anabolic and Antiresorptive Therapy for Osteoporosis -- Combination and Sequential Approaches. Bone. DOI PubMed
22. [22] Tabacco G, Bilezikian JP. (2019). Osteoanabolic and Dual Action Drugs. Br J Clin Pharmacol. DOI PubMed
23. [23] Gilsenan AW, Midkiff KD, Harris EC, et al. (2021). Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study. J Bone Miner Res. DOI PubMed
24. [24] Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. (2008). Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women with Severe Osteoporosis with and without Prior Antiresorptive Treatment. J Bone Miner Res. DOI PubMed
25. [25] Diez-Perez A, Marin F, Eriksen EF, et al. (2020). Effects of Teriparatide on Hip and Upper Limb Fractures in Patients with Osteoporosis (VERO Clinical Fracture Analysis). Osteoporos Int. DOI PubMed